World Health Organization to resume Hydroxychloroquine coronavirus trials
Representative image  |  Photo Credit: ANI
- Hydroxychloroquine Coronavirus trials will resume after brief suspension
- WHO executive group to communicate with principal investigators in HCQ trial
- More than 3500 patients recruited in 35 countries in in the solidarity trial
New Delhi: The World Health Organization (WHO) today announced that it will resume the clinical trials of Hydroxychloroquine (HCQ) after it briefly suspended the anti-malarial drug trial following a safety review.
“On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol…. The executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm,” WHO chief Tedros Adhanom said during a virtual briefing.
The WHO chief said that the decision was taken as a precaution while the safety data were reviewed adding that the Executive Group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial.
“The Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the solidarity trial…So far, more than 3500 patients have been recruited in 35 countries,” he added.
The move comes days after the Indian Council of Medical Research (ICMR) wrote to WHO on its decision to suspend HCQ trials on the basis of the finding in the study by the medical journal, The Lancet.
The ICMR also published a study in which consumption of four or more doses of an anti-malarial drug, HCQ, showed a significant decline of COVID-19 infection in health care workers (HCWs).
“It was identified that simply initiating HCQ prophylaxis did not reduce the odds of acquiring SARS-CoV-2 infection among HCWs. However, with the intake of four or more maintenance doses of HCQ, the protective effect started emerging, and in the adjusted multivariate model, a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the HCWs was identified with the intake of six or more doses of HCQ prophylaxis,” the study said.
The Health Ministry, ICMR & CSIR wrote separate letters to WHO backing the claim of HCQ prophylaxis in the frontline COVID-19 workers and the caretakers of the patients.